Cixutumumab

From Self-sufficiency

Revision as of 21:23, 23 February 2010 by Anypodetos (Talk) (Added mab_type, updated source; slight rephrasing)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Cixutumumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	IGF-1 receptor
Identifiers
CAS Number	947687-12-9
ATC code	none
Chemical data
Formula	C₆₅₀₀H₁₀₀₅₂N₁₇₂₄O₂₀₃₆S₄₄
Molar mass	146.3 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Cixutumumab is a monoclonal antibody for the treatment of solid tumors.^[1]^[2]

This drug was developed by ImClone Systems Inc.

References

↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
↑ McKian, KP; Haluska, P (2009). "Cixutumumab". Expert opinion on investigational drugs. 18 (7): 1025–33. doi:10.1517/13543780903055049. PMID 19548856.

v t e Human monoclonal antibodies ("-u-")
"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Fresolimumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab, Zanolimumab
"-kinu-" (interleukin as target)	Briakinumab, Canakinumab, Ustekinumab
"-tumu-"/"-tu-" (tumor)	Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Necitumumab, Ofatumumab, Olaratumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab
"-osu-" (bone)	Denosumab
"-mulu-" (musculoskeletal)	Stamulumab^†
"-fungu-" (fungal)	Efungumab
"-viru-" (viral)	Exbivirumab, Foravirumab, Libivirumab, Rafivirumab, Regavirumab, Sevirumab, Tuvirumab
"-bacu-" (bacterial)	Nebacumab, Panobacumab, Raxibacumab
"-ciru-" (cardiovascular)	Ramucirumab
"-neru-" (neurologic)	Gantenerumab
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.